HCW Biologics Inc. (HCWB)
0.36
0.02 (5.14%)
At close: Jan 15, 2025, 11:45 AM
undefined% (undefined)
| Bid | 0.34 |
| Market Cap | 13.81M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.01 |
| PE Ratio (ttm) | -0.36 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.36 |
| Volume | 78,632 |
| Avg. Volume (20D) | 9,720,406 |
| Open | 0.34 |
| Previous Close | 0.34 |
| Day's Range | 0.33 - 0.38 |
| 52-Week Range | 0.28 - 2.52 |
| Beta | undefined |
About HCWB
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata ...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 20, 2021
Employees 45
Stock Exchange NASDAQ
Ticker Symbol HCWB
Website https://www.hcwbiologics.com
Analyst Forecast
According to 1 analyst ratings, the average rating for HCWB stock is "Buy." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
1 month ago ·
Source
+320.91%
HCW Biologics shares are trading higher after the ...
Unlock content with
Pro Subscription
5 months ago ·
Source
-13.62%
HCW Biologics shares are trading lower after the company reported a year-over-year decrease in Q2 EPS results.
